PAJUNK® Expands U.S. Headquarters in Alpharetta, Georgia
Facility Growth Adds 30,000 Square Feet to Strengthen Warehouse, Cleanroom Production, and Office Capabilities ALPHARETTA, Ga., Oct. 16, 2025 /PRNewswire/...
Neurology
Women are more vulnerable to brain diseases – New UCLA research explains why and points to promising treatment
LOS ANGELES, Oct. 15, 2025 /PRNewswire/ -- Women are twice as likely as men to develop Alzheimer's disease (AD) and multiple...
Digital Health Market Size to Worth USD 2688 Billion by 2035 at 22.55% CAGR | Vantage Market Research
NEW YORK, Oct. 15, 2025 /PRNewswire/ -- The Global Digital Health Market is projected to grow from USD 288.55 billion in...
Global Wellness Summit Unveils Packed 3-Day Agenda for 2025 Conference in Dubai, November 18-21
This year's conference represents a first: it brings together an extraordinarily diverse array of experts for a high-level, "get real"...
Tr1X Announces FDA Clearance of IND Application for TRX319, a First-in-Class Allogeneic CAR-Tr1 Treg Cell Therapy for Progressive Multiple Sclerosis, and $50 Million in Additional Financing
On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy...
Cabaletta Bio Announces Appointment of Steve Gavel as Chief Commercial Officer and Award of Inducement Grant
– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI®...
BPGbio Welcomes Sheikh Dr. Khalid Bin Jabor Al Thani as Executive in Residence
Distinguished cancer leader to advise BPGbio leadership on acceleration of NAi platform globally and BPM 31510 oncology franchise for Precision...
Boehringer and Click Therapeutics present pivotal data for investigational prescription digital therapeutic CT-155 showing a statistically significant reduction in negative symptoms of schizophrenia
CONVOKE was the first and only pivotal trial to show a statistically significant reduction in experiential negative symptoms of schizophrenia...
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in...
Cabaletta Bio Presents First Rese-cel Data with No Preconditioning Demonstrating Biologic Activity and Early Clinical Responses at the 2025 ESGCT Annual Congress
– Complete B cell depletion, rapid reduction in autoantibodies and near-complete resolution of clinical symptoms in two of three refractory...
Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research
New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development. FREMONT, Calif., Oct. 9,...
Medtronic BrainSense™ Adaptive Deep Brain Stimulation named a 2025 TIME Best Inventions
TIME Best Inventions honors extraordinary innovations changing lives DUBLIN, Oct. 9, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader...
Kneu Health Secures $5.6M to Scale Next-Generation Neurology Care
Built on one of the world's largest Parkinson's and dementia datasets and adopted across major U.S. health systems and NHS Trusts,...
Bausch Health Announces Results of Special Meeting of Shareholders
LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the...
Bausch Health Announces Results of Special Meeting of Shareholders
LAVAL, QC / ACCESS Newswire / October 9, 2025 / Bausch Health Companies Inc. (the "Company") (NYSE:BHC)(TSX:BHC) today announced the...
Alterity Therapeutics Presents Positive Data from ATH434 Phase 2 Trial at the 2025 International Congress of Parkinson’s Disease and Movement Disorders
– Data demonstrate ATH434 slows disease progression and stabilizes orthostatic hypotension – – New analysis increases overall confidence in the...
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Event to be held October 14th at 4 p.m. ESTBETHESDA, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc....
Italfarmaco Appoints Francesco Di Marco as Chief Executive Officer
MILAN, Italy, October 09, 2025 – Italfarmaco S.p.A. today announced that Dr. Francesco Di Marco has been appointed as Chief...
Theranica Brings First-in-Class, Drug-Free Migraine Care to the Forefront at CNS 2025 with Product Theater and New Real-World Evidence
With a dedicated product theater and new real-world evidence posters, Theranica will spotlight how the Nerivio® REN wearable is reshaping...
Momentum Celebrates Winners of Premier Patient Support Awards: The GoMentum Awards 2025
INDIANAPOLIS, Oct. 8, 2025 /PRNewswire/ -- Momentum Life Sciences announces the winners of the premier Patient Support Awards, known as...